dne Pharma AS

Enovis (NYSE: ENOV) this week announced it signed a definitive agreement to acquire the Seal external fixation product line from DNE. The financial details of the deal were not disclosed. The company said the transaction is subject to customary closing conditions and is expected to close toward the end of the second quarter of 2023. “We are proud of the foundation we have built in the hindfoot segment with clinically differentiated products such as DynaNail, DynaNail Helix and Arsenal Ankle, and we are excited to further broaden our range of solutions with the addition of this leading external fixation line,” Gary Justak, president and GM of Enovis Foot & Ankle, said in a news release. “The acquisition of these great products demonstrates our commitment to the Foot & Ankle space as we continue to disrupt the market and provide innovative, comprehensive solutions for surgeons and their patients.” DNE’s Seal is a foot and ankle external fixation device. It has a speed frame, mini rail, circular frame, and pin-to-bar frame to aid in treating foot and ankle deformities, fractures and fusions. Its rail system was recently FDA-approved and can be used for everyday applications in the forefoot and rear foot but can be used interchangeably with the Seal circular frame. Enovis continues to expand its foot and ankle portfolio through other internal developments and acquisitions. It recently launched its DynaClip Delta, Quattro, Infix with Contractor technology and Star ankle PSI.